DOCSLIB.ORG

Health Plan Insights

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Plan Insights Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Enspryng Genentech, Inc. Injection, For the treatment of neuromyelitis optica August 14, 2020 (satralizumab- 120 mg/mL spectrum disorder (NMOSD) in adult patients mwge) who are anti-aquaporin-4 (AQP4) antibody positive. Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 2 TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Kesimpta Novartis Injection, For the treatment of relapsing forms of August 20, 2020 (ofatumumab) Pharmaceutical 20 mg/0.4 mL multiple sclerosis (MS), to include clinically Corporation isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Winlevi Cassiopea Inc. Cream, For the topical treatment of acne vulgaris in August 26, 2020 (clascoterone) 1% patients 12 years of age and older. Sogroyo Novo Nordisk Inc. Injection, For the replacement of endogenous growth August 28, 2020 (somapacitan- 6.7 mg/mL hormone (GH) in adults with growth hormone beco) deficiency (GHD). New Combinations and Formulations TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Vasopressin AM Regent IV Solution, To increase blood pressure in adults with August 3, 2020 (vasopressin) 20 units/mL vasodilatory shock who remain hypotensive despite fluids and catecholamines. Xtandi Atellas Tablets, For the treatment of patients with: (1) August 4, 2020 (enzalutamide) 40 mg and 80 mg castration-resistant prostate cancer; (2) metastatic castration-sensitive prostate cancer. Cystadrops Recordati Rare Ophthalmic For the treatment of corneal cystine crystal August 19, 2020 (cysteamine) Diseases Solution, deposits in adults and children with 3.8 mg/mL cystinosis. Xaracoll Innocoll Implant, For use in adults for placement into the August 28, 2020 (bupivacaine Pharmaceuticals 300 mg surgical site to produce postsurgical hydrochloride) analgesia for up to 24 hours following open inguinal hernia repair. New Generics APPROVAL GENERIC NAME TRADE NAME DOSAGE FORM MANUFACTURER(S) DATE Ciprofloxacin and Ciprodex Otic Dr. Reddy's Laboratories Ltd. August 10, 2020 Dexamthasone Suspension/Drops Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 3 Pipeline New Medication Pipeline ANTICIPATED MECHANISM OF DRUG NAME GENERIC NAME ROUTE INDICATION(S) APPROVAL ACTION DATE Lucassin Terlipressin Acetate Intravenous Vasopressin agonist Hepatorenal syndrome 09/12/2020 Ryoncil Remestemcel-L Intravenous Stem cell therapy Graft versus host 09/30/2020 disease REGN-EB3 TBD Intravenous Antiviral antibodies Ebola virus disease 10/25/2020 Bronchitol Mannitol Inhaled Mucolytic Cystic fibrosis 11/01/2020 SPN-812 Viloxazine Oral Norepinephrine Attention deficit 11/08/2020 Hydrochloride reuptake inhibitor hyperactivity disorder BIVV009 Sutimlimab Intravenous Complement Cold agglutinin disease 11/13/2020 inhibitors ALKS 3831 Olanzapine; Oral Opioid antagonist Schizophrenia Bipolar 11/15/2020 Samidorphan Atypical antipsychotic disorder I or II AR19 Amphetamine Oral CNS stimulant Attention deficit 11/15/2020 hyperactivity disorder JCAR017 Lisocabtagene Intravenous Chimeric antigen Diffuse large B cell 11/16/2020 Maraleucel receptor T-cell (CAR- lymphoma T) immunotherapy Cellular immunotherapy Zokinvy Lonafarnib Oral Farnesyltransferase Progeria 11/20/2020 inhibitor Xofluza Baloxavir marboxil Oral Endonuclease Prophylaxis of influenza 11/23/2020 inhibitor RM-493 Setmelanotide Subcutaneous Peptide melanocortin Obesity 11/27/2020 receptor agonist Danyelza Naxitamab Injectable Anti-GD2 antibody Neuroendocrine tumors 11/30/2020 (NETs) Hetlioz Tasimelteon Oral Melatonin receptor Sleep disorders 12/01/2020 agonist associated with Smith- Magenis syndrome ALN-GO1 Lumasiran Subcutaneous Antisense Primary hyperoxaluria 12/03/2020 oligonucleotide Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 4 ANTICIPATED MECHANISM OF DRUG NAME GENERIC NAME ROUTE INDICATION(S) APPROVAL ACTION DATE Orladeyo Berotralstat Oral Plasma kallikrein Prophylaxis against 12/03/2020 inhibitor angioedema attacks in hereditary angioedema FG-4592 Roxadustat Oral Hypoxia-inducible Anemia due to kidney 12/20/2020 factor (HIF) stabilizer disease Relugolix Relugolix Oral Gonadotropin- Prostate cancer 12/20/2020 releasing hormone (GnRH) antagonist RVT-901 Vibegron Oral Beta adrenergic Overactive bladder 12/26/2020 agonist symptoms Ontinua ER Arbaclofen Oral GABA receptor Spasticity in multiple 12/29/2020 agonist sclerosis KX2-391 Tirbanibulin Topical Tubulin inhibitor Src Actinic keratosis 12/30/2020 kinase inhibitor Tanezumab Tanezumab Subcutaneous Anti-NGF antibody Osteoarthritis pain 12/2020 Inclisiran Inclisiran Subcutaneous PCSK9 inhibitor Atherosclerotic vascular 4Q 2020 disease risk due to hypercholesterolemia TSR-042 Dostarlimab Injectable Programmed cell Endometrial cancer 4Q 2020 death 1 (PD-1) inhibitor MK-1242 Vericiguat Oral Guanylate cyclase Heart failure 01/20/2021 stimulants LY03005 Ansofaxine Oral Norepinephrine- Major depressive 01/2021 Hydrochloride dopamine reuptake disorder inhibitor (NDRI) Serotonin- norepinephrine reuptake inhibitor (SNRI) StrataGraft TBD Other Organ replacement Burns 02/02/2021 Evinacumab Evinacumab Intravenous Anti-angiopoietin-like Homozygous familial 02/11/2021 protein 3 (ANGPTL3) hypercholesterolemia antibody Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 5 ANTICIPATED MECHANISM OF DRUG NAME GENERIC NAME ROUTE INDICATION(S) APPROVAL ACTION DATE TGR-1202 Umbralisib Oral Phosphoinositide 3- Marginal zone 02/15/2021 kinase (PI3K) inhibitor lymphoma Trilaciclib Trilaciclib Intravenous CDK4/6 dual inhibitor Small cell lung cancer 02/15/2021 Amondys 45 Casimersen Intravenous Antisense Duchenne muscular 02/25/2021 oligonucleotide dystrophy Defencath Taurolidine; Heparin Other Anti-infective Catheter related 02/28/2021 Heparins and bloodstream infections heparinoid-like agents Oraxol Encequidar; Oral Mitotic inhibitor P- Breast cancer 02/28/2021 Paclitaxel glycoprotein (P-gp) pump inhibitor Ygalo View Melflufen Intravenous Alkylating agent Multiple myeloma 02/28/2021 Comments MSC2156119J Tepotinib Oral C-Met inhibitor Non-small cell lung 02/2021 View Comments cancer P1101 Ropeginterferon alfa- Subcutaneous Pegylated interferons Polycythaemia Vera 02/2021 2b BIIB037 Aducanumab Intravenous Amyloid beta protein Alzheimer's disease 03/07/2021 inhibitor ZP4207 Dasiglucagon Subcutaneous Glucagon analog Improve glycemic control 03/27/2021 in type 1 and/or type 2 diabetes Tivozanib Tivozanib Oral Vascular endothelial Kidney cancer 03/31/2021 growth factor receptor (VEGFR) inhibitor Ryplazim Plasminogen Intravenous Enzyme replacement Hypoplasminogenemia 03/2021 therapy ACT-128800 Ponesimod Oral Sphingosine 1- Relapsing multiple 1Q 2021 phosphate (S1P) sclerosis receptor modulators Cabenuva Cabotegravir; Intramuscular Non-nucleoside HIV-1 infection* 1Q 2021 Rilpivirine reverse transcriptase inhibitor (NNRTI) Integrase strand Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 6 ANTICIPATED MECHANISM OF DRUG NAME GENERIC NAME ROUTE INDICATION(S) APPROVAL ACTION DATE transfer inhibitor (INSTI) Relugolix Relugolix Oral Gonadotropin- Uterine fibroids 06/01/2021 releasing hormone (GnRH) antagonist TGR-1202 Umbralisib Oral Phosphoinositide 3- Follicular lymphoma 06/15/2021 kinase (PI3K) inhibitor TransCon hGH Lonapegsomatropin Subcutaneous Growth hormone Pediatric growth 06/25/2021 hormone deficiency Estelle Drospirenone; Oral Estrogens Progestins Pregnancy prevention 2Q 2021 Estetrol Ibsrela Tenapanor Oral Sodium-hydrogen Hyperphosphatemia in 2Q 2021 exchanger (NHE) end stage renal disease inhibitor NexoBrid TBD Topical Proteolytic enzymes Wound debridement 2Q 2021 Orelvo Voclosporin Oral Immunosuppressant Lupus nephritis
Load more

Recommended publications
  • Application Withdrawal Assessment Report for Luveniq
    Committee for Medicinal Products for Human Use (CHMP) Assessment report Luveniq voclosporin Procedure No.: EMEA/H/C/002069//0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 5 1.1. Submission of the dossier.................................................................................... 5 1.2. Steps taken for the assessment of the product ....................................................... 6 2. Scientific discussion ................................................................................ 7 2.1. Introduction ...................................................................................................... 7 2.2. Quality aspects .................................................................................................. 8 2.2.1. Introduction ................................................................................................... 8 2.2.2. Active Substance............................................................................................. 8 2.2.3. Finished Medicinal Product .............................................................................
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Revlimid U.S. Full Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION • FL or MZL: 20 mg once daily orally on Days 1-21 of repeated 28-day cycles for up to These highlights do not include all the information needed to use REVLIMID® safely 12 cycles (2.4). and effectively. See full prescribing information for REVLIMID. • Renal impairment: Adjust starting dose based on the creatinine clearance value (2.6). • For concomitant therapy doses, see Full Prescribing Information (2.1, 2.4, 14.1, 14.4). REVLIMID (lenalidomide) capsules, for oral use Initial U.S. Approval: 2005 ------------------------- DOSAGE FORMS AND STRENGTHS ------------------------- Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg (3). WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, -------------------------------- CONTRAINDICATIONS -------------------------------- and VENOUS and ARTERIAL THROMBOEMBOLISM • Pregnancy (Boxed Warning, 4.1, 5.1, 8.1). See full prescribing information for complete boxed warning. • Demonstrated severe hypersensitivity to lenalidomide (4.2, 5.9, 5.15). EMBRYO-FETAL TOXICITY --------------------------- WARNINGS AND PRECAUTIONS --------------------------- • Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study similar to birth defects caused by thalidomide • Increased Mortality: serious and fatal cardiac adverse reactions occurred in patients in humans. If lenalidomide is used during pregnancy, it may cause birth with CLL treated with REVLIMID (lenalidomide) (5.5). defects or embryo-fetal death. • Second Primary Malignancies (SPM): Higher incidences of SPM were observed in • Pregnancy must be excluded before start of treatment. Prevent pregnancy controlled trials of patients with MM receiving REVLIMID (5.6). during treatment by the use of two reliable methods of contraception (5.1). • Increased Mortality: Observed in patients with MM when pembrolizumab was added REVLIMID is available only through a restricted distribution program, called the to dexamethasone and a thalidomide analogue (5.7).
    [Show full text]
  • Benlysta® (Belimumab)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1227-6 Program Prior Authorization/Notification Medication Benlysta® (belimumab)* *This program applies to the subcutaneous formulation of belimumab P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021 Effective Date 10/1/2021; Oxford only: 10/1/2021 1. Background: Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 2. Coverage Criteria: A. Systemic Lupus Erythematosus 1. Initial Authorization a. Benlysta will be approved based on all of the following criteria: (1) Diagnosis of systemic lupus erythematosus -AND- (2) Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB] -AND- (3) Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate] -AND- (4) Patient does not have severe active central nervous system lupus -AND- (5) Patient is not receiving Benlysta in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)] © 2021 UnitedHealthcare Services, Inc. 1 (b) Lupkynis (voclosporin) Authorization will be issued for 12 months.
    [Show full text]
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • Revlimid-INN Lenalidomide
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Revlimid 2.5 mg hard capsules Each capsule contains 2.5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 73.5 mg of lactose (as anhydrous lactose). Revlimid 5 mg hard capsules Each capsule contains 5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 147 mg of lactose (as anhydrous lactose). Revlimid 7.5 mg hard capsules Each capsule contains 7.5 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 144.5 mg of lactose (as anhydrous lactose). Revlimid 10 mg hard capsules Each capsule contains 10 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 294 mg of lactose (as anhydrous lactose). Revlimid 15 mg hard capsules Each capsule contains 15 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 289 mg of lactose (as anhydrous lactose). Revlimid 20 mg hard capsules Each capsule contains 20 mg of lenalidomide. Excipient(s) with known effect Each capsule contains 244.5 mg of lactose (as anhydrous lactose).
    [Show full text]
  • Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
    cancers Review Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma Fatih M. Uckun 1,2,3 1 Norris Comprehensive Cancer Center and Childrens Center for Cancer and Blood Diseases, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, CA 90027, USA; [email protected] 2 Department of Developmental Therapeutics, Immunology, and Integrative Medicine, Drug Discovery Institute, Ares Pharmaceuticals, St. Paul, MN 55110, USA 3 Reven Pharmaceuticals, Translational Oncology Program, Golden, CO 80401, USA Simple Summary: This article provides a comprehensive review of new and emerging treatment strategies against multiple myeloma that employ precision medicines and/or drugs capable of improving the ability of the immune system to prevent or slow down the progression of multiple myeloma. These rationally designed new treatment methods have the potential to change the therapeutic landscape in multiple myeloma and improve the long-term survival outcome. Abstract: SeverFigurel cellular elements of the bone marrow (BM) microenvironment in multiple myeloma (MM) patients contribute to the immune evasion, proliferation, and drug resistance of MM cells, including myeloid-derived suppressor cells (MDSCs), tumor-associated M2-like, “alter- natively activated” macrophages, CD38+ regulatory B-cells (Bregs), and regulatory T-cells (Tregs). These immunosuppressive elements in bidirectional and multi-directional crosstalk with each other inhibit both memory and cytotoxic effector T-cell populations as well as natural killer (NK) cells. Immunomodulatory imide drugs (IMiDs), protease inhibitors (PI), monoclonal antibodies (MoAb), Citation: Uckun, F.M. Overcoming the Immunosuppressive Tumor adoptive T-cell/NK cell therapy, and inhibitors of anti-apoptotic signaling pathways have emerged as Microenvironment in Multiple promising therapeutic platforms that can be employed in various combinations as part of a rationally Myeloma.
    [Show full text]
  • Early Endothelial Dysfunction Severely Impairs Skin Blood Flow
    Early Endothelial Dysfunction Severely Impairs Skin Blood Flow Response to Local Pressure Application in Streptozotocin-Induced Diabetic Mice Dominique Sigaudo-Roussel, Claire Demiot, Be´renge`re Fromy, Audrey Koı¨tka, Georges Lefthe´riotis, Pierre Abraham, and Jean Louis Saumet Pressure-induced vasodilation (PIV) is a mechanism al. (2) demonstrated a major role for vasodilators such as whereby skin blood flow increases in response to pro- the calcitonin gene–related peptide and endothelial vaso- gressive locally applied pressure. Skin blood flow in dilators such as nitric oxide (NO) and prostaglandins in response to applied pressure decreased early in diabetic animal studies. In a recent study, we observed in diabetic patients as a result of vascular and/or neural impair- patients an early decrease of skin blood flow in response ment. This study was designed to determine the effect of to locally applied pressure that could be involved in the vascular changes on PIV in 1-week streptozotocin-in- development of diabetic ulceration (3). However, it was duced diabetic mice. We assessed cutaneous microvas- cular response to local increasing pressure application unclear whether skin blood flow alteration during diabetes measured by laser Doppler flowmetry (LDF) and endo- depends directly on vascular and/or neural alterations. thelium-dependent and -independent vasodilation by Diabetes through hyperglycemia is widely known to be iontophoretic delivery of acetylcholine and sodium ni- a major factor that leads to microvascular and neural troprusside and sciatic motor nerve conduction velocity complications (4). Indeed, hyperglycemia-induced end- and morphometry. In control mice, LDF increased 34% organ damage in diabetes is associated with increased flux from baseline to 0.2 kPa external pressure, showing PIV of glucose through 1) the polyol metabolic pathway response.
    [Show full text]
  • Prior Authorization Lupkynis™ (Voclosporin Capsules)
    Cigna National Formulary Coverage Policy Prior Authorization Lupkynis™ (voclosporin capsules) Table of Contents Product Identifier(s) National Formulary Medical Necessity ................ 1 79744 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 3 Revision History ................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation.
    [Show full text]